Skip to main content
. 2019 Jul 29;10(5):1893–1907. doi: 10.1007/s13300-019-0671-x

Fig. 1.

Fig. 1

Treatment algorithm based on the main findings on statements for each patient profile. T2D Type 2 diabetes, DPP4-I dipeptidyl peptidase-4 inhibitor, SU sulfonylurea, HT hypertension, HF heart failure, SGLT2-I sodium/glucose cotransporter-2 inhibitor, BMI body mass index, GLP1-RA glucagon-like peptide-1 receptor agonist, eGFR estimated glomerular filtration rate